Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2381945
Max Phase: Preclinical
Molecular Formula: C25H25FN4O3
Molecular Weight: 448.50
Molecule Type: Small molecule
Associated Items:
ID: ALA2381945
Max Phase: Preclinical
Molecular Formula: C25H25FN4O3
Molecular Weight: 448.50
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)OC(=O)N([C@H]2CC[C@H](n3c(=O)[nH]c4cc(C#N)c(F)cc43)CC2)[C@H]1c1ccccc1
Standard InChI: InChI=1S/C25H25FN4O3/c1-25(2)22(15-6-4-3-5-7-15)30(24(32)33-25)18-10-8-17(9-11-18)29-21-13-19(26)16(14-27)12-20(21)28-23(29)31/h3-7,12-13,17-18,22H,8-11H2,1-2H3,(H,28,31)/t17-,18-,22-/m0/s1
Standard InChI Key: KOIGSPGBVAOKRC-SPEDKVCISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 448.50 | Molecular Weight (Monoisotopic): 448.1911 | AlogP: 4.80 | #Rotatable Bonds: 3 |
Polar Surface Area: 91.12 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.86 | CX Basic pKa: | CX LogP: 4.47 | CX LogD: 4.47 |
Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.62 | Np Likeness Score: -0.71 |
1. Bregman H, Chakka N, Guzman-Perez A, Gunaydin H, Gu Y, Huang X, Berry V, Liu J, Teffera Y, Huang L, Egge B, Mullady EL, Schneider S, Andrews PS, Mishra A, Newcomb J, Serafino R, Strathdee CA, Turci SM, Wilson C, DiMauro EF.. (2013) Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors., 56 (11): [PMID:23701517] [10.1021/jm4000038] |
2. (2016) Oxazolidinone compounds and derivatives thereof, |
Source(2):